The intractable pain condition finally getting a genuinely new drug class is chronic neuropathic pain — and the breakthrough is a selective NaV1.8 sodium channel blocker called suzetrigine, sold under the brand name JOURNAVX. Approved by the FDA on January 30, 2025, suzetrigine is the first fundamentally new type of pain medication to reach patients in over 25 years, since COX-2 inhibitors arrived in 1999. Unlike opioids, it works exclusively on peripheral pain-sensing neurons, carries no addictive potential, and causes no sedation. For the estimated 50 million Americans living with chronic pain — and particularly the 20 million dealing with high-impact chronic pain that resists existing treatments — this is not incremental progress. It is a different mechanism entirely.
While suzetrigine’s current FDA approval covers moderate-to-severe acute pain in adults, the real story is where it is headed next. Vertex Pharmaceuticals has already secured FDA Breakthrough Therapy designation for suzetrigine in diabetic peripheral neuropathy, one of the most common and stubbornly difficult chronic pain conditions to treat. Phase 3 trials are underway, with results expected between 2026 and 2027. And suzetrigine is not alone: approximately half a dozen pharmaceutical companies are now developing their own NaV1.8 inhibitors, alongside entirely separate drug classes targeting migraine, neuropathic pain, and other conditions that have long been considered treatment-resistant. This article covers how these drugs work, who they may help, what the clinical evidence actually shows — including the setbacks — and what the next several years of pain medicine may look like.
Table of Contents
- How Does a Selective Sodium Channel Blocker Treat Intractable Pain Differently?
- What the Clinical Trials Actually Show — And Where They Have Fallen Short
- The Pipeline Beyond Suzetrigine — New Drug Classes Targeting Pain From Multiple Angles
- What This Means for Patients Currently Managing Intractable Pain
- The Opioid Crisis Context and Why Regulators Are Watching Closely
- What Caregivers and Families Should Know
- The Next Three Years in Pain Medicine
- Conclusion
- Frequently Asked Questions
How Does a Selective Sodium Channel Blocker Treat Intractable Pain Differently?
To understand why suzetrigine matters, you need to understand what it does not do. Opioids work by binding to receptors in the central nervous system — the brain and spinal cord — which is why they cause sedation, euphoria, respiratory depression, and addiction. Gabapentinoids like pregabalin also act centrally, producing dizziness, cognitive fog, and dependence in many patients. For someone with diabetic neuropathy whose feet burn constantly, or a person with post-surgical nerve damage that never resolved, these side effects can be nearly as debilitating as the pain itself. Suzetrigine sidesteps all of this. It selectively blocks the NaV1.8 voltage-gated sodium channel, a channel expressed only in peripheral nociceptors — the pain-sensing neurons in the dorsal root ganglia.
By shutting down pain signals before they ever reach the brain, the drug has no central nervous system activity whatsoever. This is a meaningful distinction in practice, not just in theory. A patient taking suzetrigine for post-operative pain can think clearly, drive, and function. Researchers at the Yale School of Medicine have stated that this peripheral sodium channel blocker “could revolutionize treatment for nerve pain” and that clinicians can now tell patients with confidence that “there will be new non-addictive, non-sedating pain medications.” The International Association for the Study of Pain highlighted the approval as a landmark event. For context, the opioid crisis has killed over 600,000 Americans since 1999. The demand for effective non-opioid alternatives is not academic — it is a public health emergency that has shaped FDA priorities for over a decade.
What the Clinical Trials Actually Show — And Where They Have Fallen Short
The evidence for suzetrigine in acute pain was strong enough to earn FDA approval, but the chronic pain data is more mixed, and anyone following this drug class closely should understand the full picture. In diabetic peripheral neuropathy, a Phase 2 study showed proof-of-concept with statistically significant pain reduction, which prompted the FDA to grant Breakthrough Therapy designation — a status reserved for drugs that may offer substantial improvement over existing treatments for serious conditions. Phase 3 trials are now ongoing. For painful lumbosacral radiculopathy — commonly known as sciatica — a Phase 2 trial met its primary endpoint with a statistically significant reduction on the Numeric Pain Rating Scale. However, the actual difference between the treatment group and placebo was modest: a reduction of 2.02 points versus 1.98 points for placebo.
That narrow margin raises questions about whether the effect will be clinically meaningful for individual patients, even if it clears statistical thresholds. More sobering still, a separate Phase 2 trial in December 2024 testing suzetrigine for chronic sciatica failed outright — the drug did not demonstrate superiority over placebo. This is an important caution against treating NaV1.8 inhibitors as a guaranteed solution for every chronic pain condition. Chronic pain is not one disease; it is dozens of conditions with overlapping but distinct mechanisms, and a drug that works brilliantly for one may do nothing for another. Vertex is also evaluating suzetrigine more broadly for peripheral neuropathic pain conditions, but results from those studies have not yet been reported. If you are a patient or caregiver hoping this drug will address a specific chronic pain diagnosis, the honest answer right now is: it depends on the condition, and we do not have complete data yet.
The Pipeline Beyond Suzetrigine — New Drug Classes Targeting Pain From Multiple Angles
Suzetrigine has drawn the most attention, but it is far from the only new mechanism in development. The pain treatment pipeline for the next several years includes at least four distinct drug classes that work through entirely different biological pathways, which matters because patients who do not respond to one mechanism may respond to another. Cebranopadol, developed by Tris Pharma, is a first-in-class dual nociceptin/mu-opioid receptor agonist. It achieves comparable pain relief to oxycodone but with approximately 25 percent less respiratory depression — the mechanism that kills people in opioid overdoses. An NDA submission is planned for late 2025, with FDA approval potentially arriving in 2026.
This drug still acts on opioid receptors, so it is not a clean break from the opioid paradigm, but the reduced respiratory risk is significant. For patients with severe pain who genuinely need opioid-level analgesia, cebranopadol could offer a materially safer option. On the migraine side, two new classes are emerging for patients who do not respond to CGRP inhibitors, the current standard. Lundbeck is developing PACAP inhibitors, which target pituitary adenylate cyclase-activating peptide receptors — a completely different pathway from CGRP. Meanwhile, Kallyope’s elismetrep is a TRPM8 antagonist targeting trigeminal sensory neurons, with registrational studies set to begin in mid-2026. Biohaven’s BHV-2100, a TRPM3 antagonist for migraine, is currently in a pivotal Phase 2 trial. Altogether, an estimated five to seven breakthrough pain therapies with fundamentally different mechanisms are expected to reach patients by 2028.
What This Means for Patients Currently Managing Intractable Pain
If you or someone you care for is living with chronic pain that has not responded adequately to existing medications, the practical question is what to do now — not in 2028. The answer involves realistic expectations and some strategic thinking about treatment sequencing. Suzetrigine is currently approved only for acute pain in adults, delivered as 50mg oral tablets. It is not yet indicated for chronic neuropathic pain, diabetic peripheral neuropathy, or any long-term pain condition. Off-label prescribing is at the discretion of individual physicians, but insurance coverage for off-label use is often denied, and the long-term safety profile for extended use has not been established through large-scale trials.
Patients with diabetic neuropathy specifically have reason for cautious optimism given the Breakthrough Therapy designation and ongoing Phase 3 program, but the data will not mature until 2026 or 2027. In the meantime, existing treatments — duloxetine, pregabalin, topical lidocaine, and carefully managed low-dose opioids where appropriate — remain the standard of care. The tradeoff worth understanding is this: NaV1.8 inhibitors trade the broad, central suppression of opioids for a more targeted peripheral block. That means fewer systemic side effects, but it also means these drugs may not help pain that is driven by central sensitization — a condition where the spinal cord and brain amplify pain signals even after the original peripheral injury has healed. Fibromyalgia, for example, is thought to involve substantial central sensitization, and there is currently no evidence that NaV1.8 inhibitors would be effective for it. Understanding where your pain originates — peripherally or centrally — may become increasingly important as these new drug classes reach market.
The Opioid Crisis Context and Why Regulators Are Watching Closely
The FDA’s approval of suzetrigine was not a routine drug approval. It was explicitly positioned as part of the agency’s response to the opioid epidemic, and the speed of the review reflected that urgency. But this political context cuts both ways. There is enormous pressure — from patients, from legislators, from public health officials — for non-opioid alternatives to succeed. That pressure creates a risk of overpromising before the full evidence is in. The chronic sciatica trial failure in December 2024 is a useful reality check. Chronic pain conditions are notoriously difficult to study because of high placebo response rates, the subjective nature of pain measurement, and the heterogeneity of patient populations.
A drug can be genuinely effective for a subset of patients and still fail a Phase 2 trial if the study population is too broad or the endpoint is not sensitive enough. This does not mean suzetrigine will not work for chronic pain conditions — it means the path from acute pain approval to broad chronic pain use will be longer and more uncertain than the initial headlines suggested. Patients should be wary of any provider or media outlet presenting NaV1.8 inhibitors as a universal chronic pain solution today. That may eventually prove true for some conditions, but the evidence is not there yet. Another limitation worth noting: suzetrigine’s mechanism targets peripheral nociceptors specifically. Conditions with a strong inflammatory component, a central sensitization component, or pain originating from non-neuronal sources may not respond to this drug class at all. The most honest framing is that NaV1.8 inhibitors are likely to be transformative for a specific subset of pain patients — those with clearly peripheral, nerve-driven pain — rather than for chronic pain as a monolithic category.
What Caregivers and Families Should Know
For those caring for someone with dementia or cognitive decline who also experiences chronic pain, the arrival of non-sedating pain medications carries particular significance. One of the most difficult aspects of managing pain in dementia patients is that existing treatments — opioids, gabapentinoids, even certain antidepressants used for pain — can worsen confusion, increase fall risk, and accelerate cognitive decline. A pain drug with no central nervous system activity would, in theory, allow treatment of peripheral nerve pain without these cognitive penalties.
This is especially relevant for diabetic peripheral neuropathy, which is common in older adults and frequently co-occurs with dementia. If the Phase 3 trials for suzetrigine in DPN succeed and the drug gains that indication, it could meaningfully change how pain is managed in elderly patients with cognitive impairment. That said, clinical trials for suzetrigine have not specifically enrolled or studied patients with dementia, so the safety and efficacy profile in this population remains unknown. Caregivers should discuss emerging options with their loved one’s pain specialist and neurologist rather than assuming applicability.
The Next Three Years in Pain Medicine
The period between now and 2028 may represent the most significant shift in pain treatment since the introduction of modern opioids. With five to seven new drug classes expected to reach patients — each targeting a fundamentally different biological mechanism — the treatment of chronic pain is moving from a one-size-fits-all approach toward something closer to precision medicine. Patients who fail one mechanism will have genuinely different options to try, rather than variations on the same theme.
The key milestones to watch include the Phase 3 results for suzetrigine in diabetic peripheral neuropathy, expected in 2026 to 2027; the potential FDA approval of cebranopadol in 2026; the registrational studies for elismetrep beginning mid-2026; and the readout of Biohaven’s TRPM3 antagonist pivotal trial. Each of these represents not just a new drug, but a new therapeutic mechanism that, if validated, opens the door for additional drugs in the same class. The competitive landscape is already forming: roughly half a dozen companies are developing NaV1.8 inhibitors alone, which should drive both innovation and, eventually, pricing pressure.
Conclusion
The approval of suzetrigine marks a genuine turning point for pain medicine — the first new mechanism of action in a quarter century, with the potential to treat peripheral neuropathic pain conditions without the sedation, cognitive impairment, or addiction risk of existing options. But it is a turning point, not a finish line. The current approval is limited to acute pain, the chronic pain trials have produced mixed results so far, and the drug’s mechanism inherently limits it to conditions driven by peripheral nerve signaling. None of these caveats diminish the significance of the advance; they simply define its boundaries.
For patients, caregivers, and clinicians managing intractable pain, the practical message is to stay informed without getting ahead of the evidence. The Phase 3 results for diabetic neuropathy and the broader chronic pain program will clarify who benefits most. In the meantime, the emergence of multiple new drug classes — NaV1.8 inhibitors, NOP/MOP dual agonists, PACAP inhibitors, TRPM8 and TRPM3 antagonists — signals that the era of treating all chronic pain with the same limited toolkit is ending. What replaces it will be more targeted, more mechanism-specific, and, for many patients, substantially more effective.
Frequently Asked Questions
Is suzetrigine (JOURNAVX) currently available for chronic pain conditions?
No. As of its January 2025 FDA approval, suzetrigine is indicated only for moderate-to-severe acute pain in adults. Clinical trials for chronic conditions like diabetic peripheral neuropathy are ongoing, with results expected in 2026 to 2027. Any use for chronic pain at this time would be off-label and at a physician’s discretion.
Can suzetrigine replace opioids for all types of pain?
Not all types. Suzetrigine targets NaV1.8 sodium channels found only in peripheral pain-sensing neurons. It is unlikely to help pain driven by central sensitization — such as fibromyalgia — or pain with a strong inflammatory component not mediated by peripheral nerves. For clearly peripheral, nerve-driven pain, it may eventually be a direct alternative to opioids.
Is suzetrigine safe for elderly patients or people with dementia?
The drug has no central nervous system activity, which is theoretically advantageous for elderly patients and those with cognitive impairment. However, clinical trials have not specifically studied these populations, so safety and efficacy data in dementia patients are not yet available.
What happens if the Phase 3 chronic pain trials fail?
A failed Phase 3 trial for one condition does not invalidate the drug for others. Suzetrigine’s acute pain approval would remain in place, and trials for other indications would continue independently. The December 2024 chronic sciatica trial failure, for instance, has not affected the ongoing diabetic neuropathy program.
Are NaV1.8 inhibitors the only new pain drug class in development?
No. At least four other new drug classes are in clinical trials for pain conditions: cebranopadol (a dual NOP/MOP agonist), PACAP inhibitors for migraine, TRPM8 antagonists, and TRPM3 antagonists. Five to seven breakthrough pain therapies are expected to reach patients by 2028.
How much does suzetrigine cost?
Pricing details and insurance coverage policies are still being established. As a first-in-class branded medication with no generic equivalent, out-of-pocket costs may be significant. Patients should check with their insurer and ask about any patient assistance programs offered by Vertex Pharmaceuticals.
